Folitab

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Folitab

What is Folitab?

Folitab is a pharmaceutical formulation primarily composed of folic acid, also known as vitamin B9. It belongs to the class of water-soluble vitamins that are essential for various metabolic processes within the human body. As a synthetic form of folate, it is used to support physiological functions that require this specific nutrient.

Mechanism and Function

Folic acid is a precursor to tetrahydrofolate, a coenzyme involved in the synthesis of nucleic acids, such as DNA and RNA. This makes it a critical component for cellular division and the growth and maintenance of all body cells. Folitab works by providing the necessary building blocks for these biological processes, ensuring that tissues with high turnover rates can function correctly.

Primary Uses

The administration of Folitab is typically focused on addressing nutritional requirements or imbalances. Its primary roles include:

  • Support for Red Blood Cell Production: It plays a vital role in the formation of healthy red blood cells. A deficiency in folate can lead to the production of abnormally large red blood cells that do not function efficiently.
  • Assistance in Cellular Repair: Because it is involved in DNA synthesis, it is necessary for the repair of tissues and the ongoing maintenance of genetic material.
  • Nutritional Supplementation: It is used to manage folate deficiency, which may arise from inadequate dietary intake, malabsorption issues, or certain physiological conditions that increase the body's demand for the vitamin.

Role in the Body

Once ingested, the active component in Folitab is converted into its metabolically active forms. These forms act as donors of one-carbon units in various enzymatic reactions. These reactions are fundamental to the metabolism of amino acids and the regulation of homocysteine levels in the blood, contributing to general biochemical stability.

Regulatory References

  1. Folic Acid - MedlinePlus
  2. Folic acid - WHO EML

What side effects are possible with Folitab?

Possible Side Effects and Safety Information

Folitab, which contains Folic Acid, is documented in official regulatory sources as having a generally low incidence of adverse reactions. Most reported effects are classified as rare.


Safety Constraint: Untreated Vitamin B₁₂ Deficiency

A critical safety consideration noted in regulatory documents is the risk of high-dose folic acid masking the hematologic signs of an underlying, untreated cobalamin (Vitamin B₁₂) deficiency. By improving blood cell counts, Folic Acid may conceal the deficiency, allowing associated, progressive neurological damage to continue unimpeded. For this reason, long-term Folitab therapy is contraindicated for use alone in individuals with untreated Vitamin B₁₂ deficiency states.


Documented Adverse Reactions

The most frequent categories of adverse events reported in labeling are related to hypersensitivity and the gastrointestinal system:

System-Organ Class Documented Adverse Reactions (Generally Rare)
Immune System Skin rash, itching (pruritus), reddened skin (erythema), and, rarely, severe reactions like anaphylaxis and bronchospasm.
Gastrointestinal Nausea, loss of appetite (anorexia), abdominal distension, and flatulence.
Nervous System Altered sleep patterns, difficulty concentrating, overactivity, confusion, and irritability, particularly associated with high-dose, extended exposure.

Serious adverse reactions primarily involve the immune system, with documented instances of anaphylaxis (including shock) and severe respiratory constriction.


Duration and Co-Administration Notes

The regulatory profile also notes that prolonged therapy may lead to a decrease in Vitamin B₁₂ serum levels. Furthermore, Folic Acid may antagonize the anticonvulsant action of phenytoin, which is a safety limitation concerning co-administration.

Overdose and Emergency Response

Overdose and when to seek help

Official Regulatory Information for Folitab

Official regulatory information states that no specific symptoms of acute overdosage are formally documented for Folic Acid. However, chronic intake of high daily doses (e.g., 15 mg/day) has been associated with nonspecific gastrointestinal disturbances (nausea, abdominal distension, bitter taste) and central nervous system effects (altered sleep patterns, confusion, irritability). Rare instances of allergic sensitization, including bronchospasm and symptoms suggestive of anaphylaxis, have also been reported.

Required Emergency Actions and Risks

  • Masking of Severe Deficiency: The most critical regulatory concern regarding excess intake (doses above 0.1 mg daily) is the risk of masking the hematological signs of Vitamin B₁₂ deficiency (pernicious anemia), which allows associated irreversible neurological damage to progress undetected. Urgent caution and medical assessment are required for individuals with undiagnosed anemia taking doses exceeding 0.4 mg daily.
  • Seeking Help: Regulatory guidance mandates that patients seek immediate medical attention or contact a Poison Control center if an overdosage is suspected. Immediate help is also required upon the manifestation of severe allergic reactions.
  • Treatment: No specific antidote is known for Folitab overdosage. Treatment procedures are confined to measures that are symptomatic and supportive, consistent with the rapid clearance and excretion of the substance.

Therapeutic Uses of Folitab

What Folitab Treats: Main Uses and Benefits

Folitab, which contains the B vitamin folic acid (also known as folate), contributes to easing the overall symptom load. Its main uses and benefits are applied across domains where additional symptomatic support is needed, primarily addressing deficiency and offering prophylaxis against specific high-risk conditions.

It is commonly used across conditions presenting with acute episodes and helps address folate deficiency megaloblastic anemia, a condition related to systemic imbalance. It is also relevant when supportive symptom management is appropriate in conditions where deficiency may occur, such as during renal dialysis or in chronic haemolytic states. These applications may assist with maintaining functional stability and contribute to improved comfort during symptomatic periods.

The application of this supplement is considered relevant in contexts involving heightened systemic burden related to pregnancy. Taking it is commonly used to help with the prevention of neural tube defects (NTDs) in the developing fetus. The therapeutic domains relevant for easing symptoms associated with acute or episodic changes include treatment of megaloblastic anemia, prophylaxis in drug-induced deficiency (e.g., methotrexate), and prevention of recurrence of neural tube defects. This supports general well-being during symptomatic phases.

“Often used during phases when symptoms become more noticeable and supportive relief is needed.”

Quick Fact: Support for Symptoms that Create Noticeable Physiological Strain

Eligibility and Restrictions for Use

Folitab is strictly contraindicated for individuals with a known hypersensitivity to the medicine or its ingredients. The medicine must not be used in patients with pernicious anemia or undiagnosed megaloblastic anemia. This is an absolute regulatory restriction to prevent Folitab from masking the hematological signs of Vitamin B12 deficiency, which could allow irreversible neurological damage to progress. Use is also restricted in patients with malignant disease unless the anemia is directly due to folate deficiency.

The use of Folitab is established across all age groups, including infants, children, and older adults. Eligibility is permitted and necessary during pregnancy and while breastfeeding, confirming these groups are not excluded from use. Certain groups require caution: routine use is not recommended for patients with coronary stents, and caution is required for patients with folate dependent tumours.

Dosage adjustments for patients with impaired renal or hepatic function are typically undefined in regulatory labeling, although use is established for those undergoing renal dialysis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Folitab (Folic Acid) has officially documented interactions structured around its metabolic role and pharmacodynamic effects, which impose administration constraints for several medicinal product categories.


Interacting Medicines and Outcomes

Category Official Interaction Outcomes
Antagonists & Anticonvulsants Co-administration with Methotrexate, a folate antagonist, may decrease the therapeutic response. Folic Acid may reduce the anticonvulsant action and serum levels of Phenytoin, Phenobarbital, and Primidone.
Drugs Affecting Folic Acid Exposure Anticonvulsants (e.g., Carbamazepine, Valproic Acid), Sulfasalazine, and Cholestyramine may impair folate absorption and increase the metabolism of circulating folate.

Administration and Substance Constraints

  • Timing Separation Rules: Antacids (containing aluminium or magnesium) must adhere to specified timing separation requirements and should not be taken within two hours after Folic Acid. Cholestyramine also requires specific administration spacing to avoid significant impairment of Folic Acid absorption.
  • Substance-Specific Alterations: Ethanol (Alcohol) is documented to increase Folic Acid elimination and decrease its absorption, a factor relevant for individuals with chronic alcohol use. Folic Acid may also reduce the intestinal absorption of Zinc-containing products.
  • Laboratory Interference: Tetracycline administration may cause false low serum and red cell folate levels due to suppression of related microbial growth.

Mechanism of Action

Folate Activation and the One-Carbon Metabolism (OCM)

Folitab, as a folic acid precursor, is biochemically activated by the dihydrofolate reductase (DHFR) enzyme into the cofactor tetrahydrofolate (THF). This process occurs primarily in the liver. THF and its derivatives carry and donate single carbon units, which is essential for the function of the central One-Carbon Metabolism (OCM) pathway.


Engaging DNA Synthesis and Cell Proliferation

Active folate cofactors directly engage in high-demand biosynthetic processes by providing the necessary carbon units for the de novo synthesis of purine and thymidylate nucleotides. This mechanism is required for DNA replication and cell proliferation by ensuring cofactor availability for nucleotide synthesis, particularly in the hematopoietic (blood-forming) and gastrointestinal systems.


Influence on Homocysteine and Methylation Capacity

Folate cofactors also influence the methionine/homocysteine cycle by assisting the enzyme methionine synthase to catalyze the conversion of homocysteine back into methionine. This action facilitates the modulation of plasma homocysteine concentrations and maintains the cellular pool of S-Adenosylmethionine (SAM), which engages in epigenetic methylation reactions.

Dosage and Administration Information

How to Use Folitab: Administration Guidelines

Folitab, which contains Folic Acid, is administered according to regimens defined to address specific needs, with the primary focus on the oral tablet form.


Administration Scope

Feature Guideline
Route of administration Oral (PO) is the preferred and most common route. Parenteral routes, including Intramuscular (IM), Intravenous (IV), or Subcutaneous (SC), are reserved for patients with severe disease or when oral absorption is known or suspected to be impaired.
Dosing schedule Therapeutic Dosing: For deficiency, regimens vary by region, with standard adult doses being 5 mg daily for approximately four months or up to 1 mg daily. High-Risk Prophylaxis: A dose of 5 mg daily is prescribed for specific preventative uses.
Timing in relation to meals The tablet is typically taken by mouth with a glass of water and may be administered with or without food.
Age-group rules Therapeutic dosing is adjusted for the pediatric population, often following the adult schedule for children over one year in some regions, while infants and younger children have lower, weight-dependent therapeutic and maintenance ranges.

Procedural and Course Structure

The usage protocol is based on daily frequency for both therapeutic and most prophylactic uses. Treatment for deficiency is usually continued for a defined duration, often until the blood picture has returned to normal. For prophylactic use in pregnancy, the regimen must begin at least four weeks before conception and continue through the first twelve weeks of pregnancy. An explicit procedural constraint is to not attempt to compensate for a missed dose by taking a double dose. This structured approach ensures adherence to the specific dose, frequency, and time course.

Recent Clinical Evidence

Research evidence / Overview of studies for Folitab

Evidence for Addressing Folic Acid Deficiency and Anemia

Research exploring the use of Folic Acid for megaloblastic anemia includes primarily historical therapeutic trials, case reports, and observational studies involving adults and children with a confirmed deficiency. These studies monitored the blood's response to the provision of Folic Acid, measuring shifts in hematological parameters like Hb and MCV. Studies consistently described patterns where the measured blood cell parameters shifted and the characteristic abnormal cell shapes were reported as resolving in the observed populations. Addressing a confirmed deficiency is a measure broadly accepted in nutritional science, but research often provides limited information for long-term outcomes or durability of the resolved deficiency status.

Evidence for Preventing Neural Tube Defects (NTDs)

The evidence base is built upon foundational randomized controlled trials (RCTs) and large-scale observational studies. This research was studied for its impact on the incidence and recurrence rate of NTDs in offspring. The key trials described findings where the measured incidence rate of NTDs was observed as reduced in groups receiving Folic Acid during the periconceptional period compared to groups that did not. Observational studies also described an association between higher maternal RBC folate status and the reported incidence of NTDs in the fetus. However, comparative evidence is lacking from new randomized trials in women of childbearing age due to the historical foundation of the finding.

Research Findings in Kidney Disease and Homocysteine Levels

Research includes multiple large-scale RCTs and systematic reviews, which were observed in patients with chronic kidney disease or ESRD on hemodialysis. The studies primarily examined the effect of Folic Acid on the biomarker homocysteine ( tHcy) levels. Trials consistently described a pattern where Folic Acid administration was associated with a measured reduction of the biomarker tHcy in this patient group. However, when researchers evaluated the clinical outcomes like cardiovascular events, the findings were mixed, with many large trials reporting that the reduction in the tHcy biomarker was not associated with a consistent reduction in heart attack or stroke rates.

Key Studies & References

  1. Folic Acid Deficiency - StatPearls (Chronic Hemolytic States and Deficiency Use)

Frequently Asked Questions (FAQ)

Common questions about Folitab (FAQ)


Q: What information is available about potential long-term effects of taking Folitab?

Official documentation notes that prolonged therapy with Folitab may be associated with a decrease in the level of Vitamin B₁₂ in the blood. Furthermore, high-dose, extended exposure has been linked to potential nervous system effects, such as difficulty concentrating and irritability. For this reason, its use is typically managed within a defined medical protocol.


Q: Can Folitab be taken with other vitamin supplements, like Vitamin B12?

Official safety information indicates that Folitab should not be used alone if a person has an untreated deficiency of Vitamin B₁₂. The safety concern noted is that Folitab may improve certain blood test results, which could mask the hematological signs of an underlying B₁₂ deficiency.


Q: Does Folitab affect how other medications, such as antibiotics, are absorbed?

Regulatory information describes specific interactions where certain medicines may affect Folitab's absorption. For example, some anticonvulsants and Cholestyramine may impair how the body takes in Folitab. The antibiotic Tetracycline has been documented to potentially interfere with the laboratory measurements of folate levels.


Q: Is Folitab intended for short-term use, or is it a long-term therapy?

The duration of Folitab use is typically defined by its purpose. For deficiency treatment, the use is typically managed for a defined course, often until the blood picture is measured to have returned to normal. For preventative uses, such as during the periconceptional period, a specific time frame is prescribed.


Q: Is Folitab needed if a person already eats a diet rich in green leafy vegetables?

Folitab contains Folic Acid, which is the stable, synthetic form of the vitamin, differing from the natural folate found in foods. The medicine is primarily intended to address a confirmed deficiency or to meet an increased physiological demand for the nutrient.


Q: Is Folitab used by older adults for any specific purpose?

According to official product information, the use of Folitab is established across all age groups, including older adults. Its general purpose is consistent with other groups: to address or prevent deficiencies where nutritional status indicates a need.


Q: What is the difference between Folitab and standard Folic Acid supplements?

Folitab is a pharmaceutical preparation that contains the active ingredient, Folic Acid (Vitamin B₉). Folic Acid is the synthetic, stable form of the vitamin, which is reliably absorbed and utilized by the body, making it the common active component in both prescription and standard supplements.


Q: Does Folitab contain iron or other minerals, or just folic acid?

Official regulatory documents identify the active ingredient in Folitab as the monocomponent Folic Acid. The product labeling details the full list of inactive ingredients, or excipients, used to create the tablet form.


Q: How does Folitab compare to L-methylfolate or other forms of folate?

Folitab contains Folic Acid, which is considered the precursor form that requires the dihydrofolate reductase (DHFR) enzyme to convert it into its active cofactors within the body. In contrast, L-methylfolate is one of the active forms that is already metabolically converted.


Q: Does current research suggest Folitab has a role in managing cognitive or neurological function?

Studies have examined the role of Folic Acid in regulating the homocysteine cycle, a metabolic pathway that has been linked to neurological processes. However, the regulatory indication for the medicine is primarily based on its established role in correcting anemia and preventing neural tube defects.


Q: Are there different versions or strengths of Folitab available?

Yes, official regulatory documents describe that Folitab is available in multiple strengths, including 5 mg and 1 mg doses, intended for different therapeutic or preventative uses. The formulation documented in official labeling is the oral tablet form.


Q: How is Folitab described for use by individuals with an established heart condition?

Official safety information indicates that the routine use is not recommended for patients who have been fitted with coronary stents. While research has shown Folitab can reduce the homocysteine biomarker, research examining cardiovascular outcomes has reported mixed results.


Q: Can Folitab be taken by people who are sensitive to certain dyes or inactive ingredients?

The medicine contains pharmaceutical excipients necessary to form the tablet. Folitab is contraindicated if a person has a known hypersensitivity to the medicine or any of its ingredients. The detailed product information provides the complete list of all components.


Q: What is the general patient expectation for follow-up testing when taking Folitab?

The treatment course for a deficiency is often scheduled to continue until the blood picture has returned to normal. Studies that established Folitab's efficacy involved monitoring shifts in hematological parameters, which suggests that monitoring through blood tests is typically necessary during the course of treatment.


Q: What is the typical time frame for the maximum effect of Folitab to be reached in the body?

Pharmacokinetic data from official sources describes that the maximum concentration of Folic Acid in the blood plasma (Tmax) is generally reached within 30 to 60 minutes after the oral dose is administered.


Q: Is Folitab considered habit-forming according to regulatory documents?

Folitab (Folic Acid) is not listed as a controlled substance by regulatory bodies. It is also not documented in official sources as having abuse potential or being a habit-forming substance.


Q: What is the official information regarding overdose symptoms for Folitab?

Regulatory sources report that Folitab is generally considered to have a wide margin of safety. While large doses are typically well-tolerated, specific information regarding acute overdose symptoms is limited, citing its low potential for toxicity.


Q: How long does Folitab typically remain effective after consumption?

Pharmacokinetic data describes that the half-life of Folic Acid in the blood plasma is approximately several hours, which can vary depending on the administered dose and the body's existing nutrient stores.


Q: Is Folitab described as helping with energy levels or fatigue?

The medicine's main purpose is to address a folic acid deficiency, which is a condition that can lead to specific types of anemia and associated symptoms. Its intended action is to correct the deficiency by supporting red blood cell formation, which may help address associated symptoms.


Q: Is Folitab recommended for individuals following a strictly plant-based diet?

Folitab is indicated for the treatment and prevention of deficiency states. Individuals adhering to specialized or restricted diets, such as plant-based diets, may be at risk of certain nutrient depletions that the medicine is indicated to address.


Q: Does taking Folitab require any specific dietary changes outside of avoiding certain beverage interactions?

Patient counseling information primarily focuses on specific substance constraints. For example, it is noted that the consumption of alcohol is documented to affect Folic Acid absorption and elimination, but broad dietary changes are not typically specified in the labeling.

How should Folitab be stored and disposed of?

Folitab (Folic Acid Tablets) must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The medicine requires protection from light and moisture to maintain the stability of the active ingredient. Tablets must be dispensed in a well-closed container that includes a child-resistant closure to keep the medication out of the sight and reach of children.


Disposal Instructions

Folitab should not be flushed down a toilet or poured down a drain. Unused or expired tablets should be disposed of using a drug take-back program. If one is unavailable, the medication may be mixed with an undesirable substance, sealed in a container, and discarded in the household trash according to official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Folitab found in:

A-Z Index: